Press page ASC Oncology
Welcome to the press page of ASC Oncology. Here we provide our press releases, press pictures and all important information about who we are and what we do.
Publications

Berlin Partner reports on ASC Oncology as a pioneer in modern cancer research and on the Reverse Clinical Engineering®, which makes advances in modern cancer research accessible to patients in the sense of personalized treatment.
August 2023

EU Startup News is calling ASC Oncology one of the 15 Biotechnology Startups with biotech breakthroughs. The “reverse clinical engineering supports both patients and physicians, showcasing a unique approach in biotech health diagnostics and therapeutics.”
June 2023

SelectScience talked to our CEO Dr Christian. Regenbrecht about bringing targeted tumor therapy to patients and the promising future of patient-derived tumor organoids.
April 2021

berlin-buch.com reports about the collaboration of Maya Niethard, MD (Sarcoma Center Helios-Hospital Berlin Buch) and Christian Regenbrecht, PHD (ASC Oncology / Cellphenomics).
January 2021

Dr. Christian Regenbrecht was a guest at the podcast “The Culture Club” and talked about 3D cell culture technologies, preclinical efficacy studies, and the changing healthcare landscape.
December 2019

Dr. Regenbrecht speaks on the Youtube channel of the Rotary Club about the treatment of cancer and the Non For Profit Organization/Network “Scientists without Borders”.
October .2014
Press releases
- Cancer does not stop at borders – and neither does an approach to personalized cancer therapy developed in Berlin. Reverse Clinical Engineering® is now available to oncologists and cancer patients in Saudi Arabia, the Middle East, and North Africa.
- Knowing what works: Thanks to a new test procedure before the start of therapy, ASC Oncology can answer the crucial question posed by both patients and oncologists of how effective cancer drugs will be on each patient’s tumor.
Press materials
Press kit
Press pictures
Logo

Your contact partner
Please feel free to contact me in case of having any further questions of if you are interested in an interview. You can reach me from Monday to Friday between 9am and 6pm.
Melanie Alperstaedt
Corporate Communication
Collaborations
FAQ
We go one step further. Sequencing tumors, for example, can reveal changes in the genetic material that may be used as a target for treatment of your tumor. However, it’s not clear if the targeted treatment will work in your case. Recent studies have shown that only a fraction of patients (0.8 – 3%) have been able to benefit from a therapy chosen for its sequencing results (Tannock & Hickman, 2019). In contrast, ASC Oncology’s Reverse Clinical Engineering® uses a person’s own tumor model to directly test the cancer drugs’ efficacy. This allows a prediction to be made about how you will respond to therapy. Find out more about the test procedure under Science.
Your treating physician removes a small piece of cancer tissue during your surgery or biopsy and sends this directly to ASC Oncology’s laboratory. Our team of scientists multiplies the living tumor cells in the lab and grows “avatars” of your tumor, called ‘tumor organoids’. These avatars of the tumor can be used to test drugs that may be candidates for treating your tumor, allowing the most effective anticancer drug to be determined before therapy begins. Our results are an important decision-making aid for personalized anticancer therapy. Compared to following standard guideline recommended therapy, this approach has higher chances of treatment success. View a complete list of steps of the procedure here.
No, ASC Oncology does not replace your oncologist, but provides you and your doctor with additional information. Every patient and every cancer is unique. The results of the Reverse Clinical Engineering® test procedure will tell you and your oncologist which drugs are likely to be effective on your individual tumor. These additional insights increase the chance of receiving effective drug therapy right from the start and avoiding ineffective therapies along with potential side effects.
It varies. Depending on the quality of the tumor sample and the cancer entity, growing PD3D® tumor models can take different amounts of time. On average, the Reverse Clinical Engineering® test procedure takes 28 days from receiving the sample to preparing the final report.
Please do not send a sample without letting us know in advance. Please contact us at 0800 6988667 or use our online form to register a patient and send a sample. We will organize the pick-up and provide everything needed to transport it as quickly as possible – even for short-term requests. Take a look at our overview of the procedure.
ASC Oncology was founded in 2019 by leading scientists in the fields of pathology, biology, biochemistry, biotechnology, and tumor biology. We are an interdisciplinary team of experts, who together with lawyers and business information specialists, are dedicated in our fight against cancer and to advance precision oncology.
ASC Oncology benefits from years of expertise in 3D cell culture and the latest findings in the field of tumor organoid research through close collaboration with its sister company CELLphenomics, which was founded in 2014. In addition, we are supported by a top-class advisory board consisting of physicians, scientists, and patient representatives.